targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
Published 6 months ago • 153 plays • Length 3:13Download video MP4
Download video MP3
Similar videos
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
1:59
assessing if a patient with dlbcl is responding to treatment using pet-ct and novel assays
-
1:02
bispecific agents: the future of aml and mds treatment?
-
3:50
antibody-based therapy in aml: immunotoxins and bites
-
2:44
dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma
-
4:31
limitations of targeted therapy for aml
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
1:36
targeted therapy for aml
-
1:59
t-cell engagers vs monoclonal antibodies for the treatment of aml: the influence of cd38 expression
-
1:55
aml: hybridoma vaccines
-
1:03
personalizing aml treatment by targeting mrd mutations
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
2:38
session highlights: transforming aml treatment and building on new approaches
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
6:38
the sequencing of cd19-targeting car-ts and cd20-targeting bispecifics in dlbcl